EKSO BIONICS (EKSO) AI Stock Analysis

• Market Cap: $17.40M
• Dividend Yield: N/A
• Average Volume (3M): 56.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.83
• Revenue Growth: -16.59%
• EPS Growth: 43.20%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.54
• Shares Outstanding: 3,392,723
• 10 Day Avg. Volume: 46,910
• 30 Day Avg. Volume: 56,843
• PEG Ratio: 0.33
• Price to Book (P/B): 14.52
• Price to Sales (P/S): 10.29
• P/FCF Ratio: -18.67
• Enterprise Value/Market Cap: 0.42
• Enterprise Value/Revenue: 0.50
• Enterprise Value/Gross Profit: 0.93
• Enterprise Value/Ebitda: -0.75
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $5.50 ▲(13.40% Upside)

EKSO BIONICS' overall stock score is primarily impacted by its financial performance, which reflects ongoing challenges with profitability and cash flow. Technical analysis provides some optimism with bullish indicators, but the valuation remains unattractive due to negative earnings. The earnings call further underscores financial difficulties, despite some positive strategic developments.

Positive Factors

Strategic Partnerships

Strategic partnerships with healthcare organizations enhance market access and distribution capabilities, potentially driving long-term revenue growth.

AI and Innovation Initiatives

Integrating AI into products can lead to enhanced functionality and differentiation, supporting competitive advantage and long-term product evolution.

Revenue Rebound

A rebound in revenue and improved margins indicate effective management and operational resilience, supporting future growth prospects.

Negative Factors

Significant Revenue Decline

A sharp revenue decline highlights potential demand issues or sales execution challenges, impacting long-term financial stability.

Decreased Gross Margin

A decrease in gross margin suggests rising costs or pricing pressures, which can erode profitability and affect long-term financial health.

Increased Net Loss

An increasing net loss indicates ongoing financial struggles, necessitating improved cost management and revenue generation for sustainability.

EKSO BIONICS Business Overview & Revenue Model

Company Description

EKSO BIONICS (EKSO) is a technology company focused on developing advanced robotic exoskeletons designed to assist individuals with mobility impairments. Operating primarily in the healthcare sector, EKSO creates innovative solutions for rehabilitation and physical therapy, enabling users to regain movement and independence. Their flagship products include the EksoGT, an exoskeleton designed for gait training in rehabilitation settings, and the EksoVest, a wearable exoskeleton that helps reduce fatigue and strain for workers in industrial settings.

How the Company Makes Money

EKSO BIONICS generates revenue through the sale of its exoskeleton products to hospitals, rehabilitation centers, and industrial clients. The company also earns income from leasing its devices, providing training and support services, and ongoing maintenance contracts. Key revenue streams include direct sales of exoskeleton systems, recurring revenue from service agreements, and partnerships with healthcare organizations and rehabilitation facilities that integrate EKSO's technology into their treatment programs. Additionally, EKSO may benefit from collaborations with research institutions and grants that support the development of innovative rehabilitation technologies.

EKSO BIONICS Financial Statement Overview

Summary

EKSO BIONICS faces ongoing financial challenges with negative profitability and cash flow metrics. Despite improvements in operational efficiency and cash flow management, persistent losses and reliance on external financing remain significant concerns. The moderate leverage and stable equity position provide some stability.

Income Statement

EKSO BIONICS has shown a volatile revenue trajectory with a slight revenue decline of 1.94% from 2023 to 2024. The gross profit margin improved to 53.06% in 2024 from 49.68% in 2023, indicating efficiency in controlling direct costs. However, the company continues to face challenges with profitability, as evidenced by a negative net profit margin of -63.21% in 2024, despite improving from -83.17% in 2023. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

EKSO BIONICS' balance sheet reflects a stable equity position with an equity ratio of 47.68% as of 2024. The debt-to-equity ratio stands at 0.47, indicating moderate leverage, which has slightly decreased from 0.57 in 2023. However, the return on equity remains negative at -89.17% due to persistent net losses, highlighting a challenging environment for shareholder returns.

Cash Flow

The cash flow statement reveals a negative free cash flow for 2024, although it improved by 19.46% compared to 2023. The operating cash flow to net income ratio is 0.87, suggesting that operational cash generation is not sufficient to cover net losses. The company is heavily reliant on financing activities to support cash flow needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.75M	17.93M	18.28M	12.91M	11.25M	8.88M
Gross Profit	7.89M	9.51M	9.08M	6.21M	6.75M	5.07M
EBITDA	-9.70M	-9.45M	-13.20M	-14.04M	-9.09M	-15.07M
Net Income	-10.43M	-11.33M	-15.20M	-15.08M	-9.76M	-15.82M
Balance Sheet
Total Assets	21.66M	26.65M	28.92M	40.90M	49.17M	20.60M
Cash, Cash Equivalents and Short-Term Investments	2.72M	6.49M	8.64M	20.52M	40.41M	12.86M
Total Debt	3.02M	5.98M	7.17M	7.50M	2.22M	3.86M
Total Liabilities	11.98M	13.95M	16.31M	15.46M	11.95M	16.16M
Stockholders Equity	9.68M	12.71M	12.61M	25.44M	37.22M	4.43M
Cash Flow
Free Cash Flow	-8.87M	-9.88M	-12.21M	-14.88M	-11.21M	-8.76M
Operating Cash Flow	-8.90M	-9.85M	-12.05M	-14.69M	-11.16M	-8.76M
Investing Cash Flow	-83.00K	-37.00K	-157.00K	-5.17M	-59.00K	0.00
Financing Cash Flow	3.39M	7.77M	348.00K	176.00K	38.71M	10.70M

EKSO BIONICS Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EKSO, the sentiment is Neutral. The current price of 4.85 is below the 20-day moving average (MA) of 4.99, above the 50-day MA of 4.71, and below the 200-day MA of 5.31, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 47.98 is Neutral, neither overbought nor oversold. The STOCH value of 53.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EKSO.

EKSO BIONICS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	64 Neutral	$7.52M	0.74	5.90%	―	-4.99%	-19.11%
HBIO	55 Neutral	$27.44M	―	-138.36%	―	-12.24%	-427.45%
EKSO	52 Neutral	$17.40M	-0.92	-85.01%	―	-16.59%	43.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
POAI	39 Underperform	$30.36M	-0.34	-708.73%	―	-38.79%	58.27%
MLSS	38 Underperform	$29.73M	-4.35	-123.50%	―	7.84%	-43.00%
LUCY	35 Underperform	$7.18M	-0.48	-83.04%	―	29.30%	70.61%

EKSO BIONICS Corporate Events

Ekso Bionics Announces $3.2 Million Stock Offering

On October 28, 2025, Ekso Bionics entered into a securities purchase agreement with institutional investors to sell 769,490 shares of its common stock at $4.81 per share in a registered direct offering. The offering is expected to close by October 30, 2025, with net proceeds of approximately $3.2 million intended for general corporate purposes, including research and development, administrative costs, and strategic initiatives. The company also entered into a placement agency agreement with Lake Street Capital Markets, LLC, which will receive a 6% cash fee and a warrant to purchase additional shares.

The most recent analyst rating on (EKSO) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.

Ekso Bionics Shows Strong Q3 Recovery and Growth

Ekso Bionics Holdings, Inc., based in San Rafael, California, is a pioneering company in exoskeleton technology, focusing on enhancing human capabilities in both medical and industrial sectors. In its third-quarter 2025 financial report, Ekso Bionics highlighted a notable recovery with a 2% year-over-year revenue growth and a significant 105% increase from the previous quarter, reaching $4.2 million. The company also reported an improved gross margin of 60.3% and a reduced net loss of $1.4 million, marking a 31% improvement from the previous year. Key financial metrics showed a decrease in operating expenses, driven by lower payroll costs due to the Employee Retention Credit, and a strategic focus on high-margin sales. Additionally, Ekso Bionics launched ‘eksoUniversity’, enhancing its educational outreach. Looking ahead, the company is exploring strategic transactions to potentially diversify its business, while continuing to execute its growth strategy. The management remains optimistic about navigating future challenges and opportunities.

Ekso Bionics’ Exoskeleton Study: A Potential Game-Changer for Health and Finance

Ekso Bionics is conducting a clinical study titled ‘Health and Financial Impact on the Use of a Personal Exoskeleton in the Home and Community: a Case Study.’ The study aims to assess the long-term use of a personal overground robotic exoskeleton in individuals with spinal cord injury. Key objectives include evaluating usage patterns, health outcomes such as heart rate and physical activity, and healthcare expenditures over a 12-month period. This research is significant as it explores the potential health and financial benefits of exoskeleton technology in real-world settings.

Ekso Bionics Secures $2M Loan for Working Capital

On September 12, 2025, Ekso Bionics entered into a Secured Promissory Note and Security Agreement with B. Riley Commercial Capital, LLC, securing a $2.0 million loan for working capital and corporate purposes. The agreement includes a 10% interest rate, a maturity date of September 14, 2026, and an option for the lender to convert the loan into equity. This move replaces a previous loan agreement with Banc of California, potentially impacting Ekso Bionics’ financial strategy and stakeholder interests by providing more flexible financing options.

The most recent analyst rating on (EKSO) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.

Ekso Bionics’ Exoskeleton Study: A Potential Game-Changer for Health and Finance

Ekso Bionics Holding is conducting a clinical study titled ‘Health and Financial Impact on the Use of a Personal Exoskeleton in the Home and Community: a Case Study.’ The study aims to explore the long-term use of a personal overground robotic exoskeleton in individuals with spinal cord injury, focusing on usage patterns, health outcomes, and healthcare expenditure over 12 months. This research is significant as it seeks to understand the potential benefits of exoskeletons in improving health and reducing medical costs.

Ekso Bionics’ Earnings Call: Mixed Results with Promising Initiatives

The recent earnings call for Ekso Bionics Holding presented a mixed sentiment. While the company faced significant declines in revenue, gross margin, and an increase in net loss, there were promising developments in the Personal Health segment, strategic partnerships, and AI initiatives. Management expressed optimism about recovering deferred sales and continued growth in Personal Health products.